Rius Medical

Rius Medical has made it its mission to further support the cell and gene therapy industry by channelling its expertise into developing technologies that enables “scale up” manufacturing processes.

Rius Medical develops proprietary cell lines for drug delivery. What we do are novel protein therapeutics and a drug delivery technology combine. The Rius Medical project is available to all investors, as published on EuroQuity ¹ and on European Investment Project Portal (EIPP) ². On Angel Invest Network (UK) www Rius Medical is seeking from business angels up to EUR 50.000 Convertible Loan at a discounted rate of 0,50 euro per share.

Lead Investor, Resource Link Consulting Group transferred EUR 1,000,000 financing and pending EUR 20,000, this project is implemented as of April 2020. An additional EUR 228,000 investment is pending Rius Medical joining SOSV IndieBio accelerator program with emphasis on IndieBio Coronavirus Initiative www.

Addressing Coronavirus is with NK cells manufacturing and providing Blood for transfusion! January 2020, Sorrento and Celularity initiated Emergency Allogeneic Natural Killer Cell Therapy Development for Coronavirus Infection www. It is the view of Rius Medical that addressing the 2019 Coronavirus outbreak must exploit NK cells as a therapeutic agent. Rius Medical believes that off-the-shelf natural killer (NK) cells therapy is to be the primary weapon in addressing the 2019 Coronavirus outbreak. The attached documents highlights why that is the case.

Regardless of the form, are we on the right track with Coronavirus vaccine? March 17, 2020, the European Commission offered up to EUR 80 million in financial support to the German biotech CureVac AG (RNA-based vaccine) after it was reported that US President Donald Trump attempted to secure exclusive access to a COVID-19 vaccine CureVac is developing www. As a secondary weapon, it is Rius Medical view that vaccine development must be performed. However, the documents in attachment highlight my support for an alternative as primary weapon. That’s because vaccines utilising mRNA platforms remain an unproven technology, with no vaccine approved for use to date www.

Bottom Line for EUR 20,000 investment: An investment of EUR 20,000 as Convertible Loan at a discounted rate of 0,50 euro per share implies EUR 2,160,000 financial benefits on FIVE products, if not EUR 420,000 financial benefits on TWO products at year 2 (i.e. December 2021). Alternatively there is the option of EUR 20,000 Classical LOAN (1 year maturity, yet full repayment at the latest mid-April 2020) with 30% interest p.a. for EUR 26,000 repayment. More information are available in the attachments.

Are you against a brief 3 minutes talk to learn more?

Many thanks and warmest regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de         

Dear Investors / Business Angels,

With Proprietary cell lines for drug delivery, Rius Medical brings novel protein therapeutics and a drug delivery technology for multiple products, as published on European Investment Project Portal (EIPP) www. As a service provider/contractor, you will find Rius Medical primarily in partnership and cooperation with business partners to bring products to the market in 2 years (i.e. within Year 2021).

Planned use of the EUR 20,000 investment: liquidity for the payment of EUR 25,600 surety bond in relation to the release of EUR 1,000,000 equity capital in the escrow account of Rius Medicals at Accrued Equities Inc.

Stem cell applications will revolutionize medicine and therapies! At the Annual Meeting of the World Economic Forum 2020 in Davos (21-24 January 2020 www), the current market for stem cell therapies grew by 36% per year and will rapidly expand as a groundbreaking treatment for non-communicable diseases or as a lifestyle factor. With greater resources and an increasingly experienced talent pool, scientists and doctors may be able to develop stem cell research to cure the world's most difficult diseases.

NK cells manufacturing against Coronavirus is in development since January 2020 with Sorrento and Celularity initiating Emergency Allogeneic Natural Killer Cell Therapy Development for Coronavirus Infection www. Rius Medical has made it its mission to further support the cell and gene therapy industry by channelling its expertise into developing technologies that enables “scale up” manufacturing processes.

In the latest March 2020 updates to investors you will find a choice regarding a EUR 20,000 investment either as a Classical LOAN (1 year maturity, yet full repayment at the latest April 2020) with 30% interest p.a or through a Convertible Loan at a discounted rate of0,50 EUR per share that implies 2.160.000 EUR financial benefits for FIVE products, if not 420.000 EUR financial benefits for TWO products at year 2 (i.e. December 2021).

Are you against a 3 minutes Briefing over a telephone/Skype call on this investment opportunity?

Denis Demarais (BSc)
Founder, CEO and Chief Scientific Officer

Rius Medical UG (Haftungsbeschränkt)
Schulstraße 16, 72178 Waldachtal
Baden Württemberg / Germany
Tel:      +49 (0) 1577-519-8090                     Skype: djdemarais
Email: denisdemarais@riusmedical.de         

Dear Investors / Business Angels,

How valuable is it for you to access Coronavirus treatment?

Vaccines to protect against Covid-19, the new Coronavirus infection: a number of vaccine projects have been launched against this infectious disease; the World Health Organisation (WHO) currently has 35 www. However, vaccines must be tested. In general, the development of vaccines is estimated to be around 15 years. For the MERS virus, which was detected in the Arabian Peninsula in 2012 and which is also one of the corona viruses, a vaccine has only been clinically tested since 2018 www.

The global NK Cell Market Research 2020 provides an overview of the business with important insights, applications and the structure of the industrial chain www. January 2020, Sorrento and Celularity initiated emergency allogeneic natural killer (NK) cell therapy development for Coronavirus infection www. Sorrento owns 25% of Celularity and the companies have a long-standing relationship. Both companies expressed interest in starting the clinical development of anti-Covid-19 allogeneic NK cell therapy. Celularity has already tested its natural killer cells against cancer in human trials where they have proven to be safe and well tolerated. March 2020, the company has just submitted an IND, an Investigational New Drug application, to the Food and Drug Administration to test NK cells against COVID-19 video.

Due to the spread of the Coronavirus, there is a decrease in blood donations for fear of Coronavirus. For example, blood donations in the university hospitals Greifswald and Rostock, Germany are becoming scarce. In addition, the spread of the Coronavirus dispenses with donors throughout Germany www. The German Red Cross also appealed to blood donors not to give up donations for fear of infection with the novel Coronavirus. The DRC/German Red Cross Blood Donation Service North-East is currently experiencing an increasing decline in the number of donors. The background is the Corona epidemic, but also the seasonal increase in cold and flu cases. Volker Kiefel, head of the Institute of Transfusion Medicine at the Medical University of Rostock, pointed out that donors are deferred from the donation for four weeks after a stay in a high-risk region or after contact with infected patients. Even after a full recovery from a confirmed infection with the Coronavirus, donors would be deferred from the donation by eight weeks www.

Stem cell applications will revolutionize medicine and therapies! At the Annual Meeting of the World Economic Forum 2020 in Davos (21-24 January 2020 www), the current market for stem cell therapies grew by 36% per year and will rapidly expand as a groundbreaking treatment for non-communicable diseases or as a lifestyle factor. With greater resources and an increasingly experienced talent pool, scientists and doctors may be able to develop stem cell research to cure the world's most difficult diseases.

Here you can find Investor Value Maximization whereby Rius Medical, by emphasizing on partnership, collaboration and working with business partners; enables investors to EXIT at year 2 (i.e. December 2021). For example, a 20.000 euro Convertible Loan at a discounted rate of 0,50 euro per share implies 2.160.000 euro financial benefit for FIVE products, if not 420.000 euro financial benefit for TWO products at year 2 (i.e. December 2021). Want to learn more? By supporting Rius Medical, you are investing in a platform technology for multiple products that drive advances in therapeutics. Rius Medical is about bringing innovation across the entire healthcare value chain. More urgently: in addressing NK cells manufacturing against Coronavirus as well as addressing the related blood donations shortages! 

Many thanks and warmest regards,

Denis Demarais
Founder and CEO
Email: denisdemarais@riusmedical.de

By contrast with just moderate world economic growth overall, conditions for industrial biotechnology continued to be positive in the 2019 financial year. Markets for biotechnology products and processes frequently differ in their trends from those for conventional products in the same application areas. Such markets frequently record significantly greater growth dynamism.

The World Economic Forum Annual Meeting 2020 in Davos, Switzerland (21—24 January 2020) viewed the current market for stem cell therapies growing at 36% per year and will rapidly expand when a breakthrough treatment for non-communicable disease or a lifestyle factor occurs (www). With greater resources and an increasingly experienced talent pool, scientists and physicians may be able to develop stem cell science to cure the world's most challenging diseases.

According to Q3 2019 data from the Alliance for Regenerative Medicine (ARM Foundation), there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering. This company, Rius Medical from its founding on 31 August 2016, is dedicated to gene-modified cell therapy.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Sector-related conditions for Rius Medical demonstrate a collaborative environment among key players. In red blood cells for drug delivery, June 2019 saw France-based Erytech Pharma announcing a $57 million Strategic Collaboration with USA-based SQZ Biotechnologies to develop cell-based therapies targeting cancer antigens and cancer cell amino acid metabolism (www). Erytech Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. To date, Erytech Pharma has not generated any revenue from the sale of its products.

Another clinical-stage biopharmaceutical company that to date has not generated any revenue from the sale of its products is Rubius Therapeutics. Nonetheless July 2018 Rubius Therapeutics joined the parade of biotech companies going public (www), raising a whopping $241.1 million to support its approach of engineering red blood cells into off-the-shelf treatments for disease, that is genetically engineering red blood cells to combat cancer and other diseases. Biotech investors’ appetite for risk in stem cell science to cure the world's most challenging diseases in that July 2018 IPO valued Rubius Therapeutics at $2 billion.

Furthermore, Advanced therapy medicinal products (ATMPs) are beginning to reach European markets. In late 2017 and early 2018 the US regulator, the FDA, approved the first two CAR T-cell therapies – Gilead’s axicabtagene ciloleucel (Yescarta), for adult patients with relapsed or refractory large B-cell lymphoma, and Novartis’s tisagenlecleucel (Kymriah), for patients up to 25 years of age with B-cell precursor ALL that is refractory or in second or later relapse (www). The European Medicines Agency (EMA) followed suit in August 2018, also approving Kymriah for use in adults with relapsed or refractory diffuse large B-cell lymphoma, on the basis of results that had become available subsequent to the FDA approval. As a result, the first two CAR T-cell therapies can now be marketed across Europe.

August 2018, ARM Foundation for Cell and Gene Medicine released Health Economic Impact Landscape Analysis, the first step to developing macroeconomic value model for regenerative medicine advanced therapies. According to Morrie Ruffin, Executive Director of the ARM Foundation, “We are in a new era of value-based medicine. A macroeconomic analytical framework is necessary to objectively assess the clinical, economic, and social impact that regenerative therapies will have on the healthcare economy.”

Here you have it - A highly lucrative money placement opportunity in stem cell science. Don’t hesitate to get in contact with Rius Medical.